Clinical trials: Advanced Solid Tumors (Phase 1)
Solid Tumor, Lymphoma
Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)
The purposes of this study are to: 1) assess the safety and tolerability and 2) establish a preliminary recommended Phase 2 dose (RP2D) and/or a maximum tolerated dose (MTD) or a maximum administered dose (MAD) of MK-2118 when…
- Trial name
- NCT03249792
- Testing
- MK-2118 (IT), MK-2118 (SC), Pembrolizumab
- Where
- 8 sites in United States, Israel
- Volunteers
- 140 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Malignant Solid Neoplasm, Recurrent Brain Neoplasm
Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors
This phase I trial studies the side effects and best dose of dasatinib and temsirolimus when given together with cyclophosphamide in treating patients with solid tumors that have spread to other places in the body, have come…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Brain Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Brain Neoplasm
- Trial name
- NCT02389309
- Testing
- Cyclophosphamide, Dasatinib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00027898
- Testing
- bortezomib, carboplatin, etoposide
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Malignancies
Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies
The objectives of this Phase I study are to determine the maximum tolerable dose (MTD) and to evaluate pharmacokinetics (PK), safety/ tolerability and preliminary efficacy of OB318 in patients with advanced solid malignancies.
- Trial name
- NCT02347228
- Testing
- OB318 capsule
- Where
- 2 sites in Taiwan
- Volunteers
- 21 people
- Sponsor
- Oneness Biotech Co., Ltd.
Lymphoid Malignancies, Solid Tumors
RTA 402 in Advanced Solid Tumors or Lymphoid Malignancies
Primary: To determine the dose-limiting toxicity, maximum tolerated dose, and recommended phase II dose of RTA 402 capsules in patients with advanced solid tumors or lymphoid malignancies who have failed standard-of-care curative…
- Trial name
- NCT00508807
- Testing
- RTA 402
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Neoplasms, Neoplasm Metastasis
A Study of AK-01 (LY3295668) in Solid Tumors
This two-part study consists of a phase 1 dose escalation study in participants with locally advanced or metastatic solid tumors, and a phase 2 portion in up to 3 groups with either small cell lung cancer, breast cancer and/or…
- Conditions
- Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms, Head and Neck Neoplasms
- Trial name
- NCT03092934
- Testing
- LY3295668
- Where
- 3 sites in Canada
- Volunteers
- 13 people
- Sponsor
- Eli Lilly and Company
Solid Tumor, Adult, Acute Myeloid Leukemia
A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
A Phase I, Open Label, Dose-Escalation, First in Human (FIH) study evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR103 Calcium in patients with relapsed advanced malignancies (BHARAT-1).
- Conditions
- Solid Tumor, Adult, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non Hodgkin Lymphoma
- Trial name
- BHARAT-1 (NCT05607199)
- Testing
- AUR103
- Where
- 5 sites in India
- Volunteers
- 27 people
- Sponsor
- Aurigene Discovery Technologies Limited
Solid Tumor
A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors
A Multicenter, Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors
- Trial name
- NCT05176509
- Testing
- YH003, YH001, Pembrolizumab
- Where
- 4 sites in Australia
- Volunteers
- 5 people
- Sponsor
- Eucure (Beijing) Biopharma Co., Ltd
Advanced Solid Tumors
A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors
The purpose of this study is to learn about the effects of a study medicine, WGI-0301 to find the best dose for treating solid tumors, and to see how safe and tolerable the study drug is for patients with solid tumors.
- Trial name
- NCT05267899
- Testing
- WGI-0301
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Zhejiang Haichang Biotech Co., Ltd.
Advanced Solid Tumor Malignancy
Study of KBA1412 in Participants With Advanced Solid Malignant Tumors
The purpose of this trial is to assess the safety and efficacy of KBA1412, a patient derived, fully human, monoclonal antibody targeting CD9, in patients with advanced solid malignant tumors
- Trial name
- NCT05501821
- Testing
- KBA1412, Pembrolizumab
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 16 people
- Sponsor
- Kling Biotherapeutics B.V.
Solid Tumours
A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors
A Phase 1, Open-Label Study of the Safety, Tolerability,Pharmacokinetics, Pharmacodynamics and Clinical Activity of AP601 in Patients with Solid Tumours.The study is designed to find the highest dose of AP601 that can be given…
- Trial name
- NCT07165067
- Testing
- AP601
- Where
- 3 sites in Australia
- Volunteers
- 36 people
- Sponsor
- AP Biosciences Inc.
Locally Advanced Solid Tumor
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion…
- Trial name
- NCT05732831
- Testing
- TNG462, Pembrolizumab
- Where
- 26 sites in United States, France and 1 more
- Volunteers
- 225 people
- Sponsor
- Tango Therapeutics, Inc.
Solid Tumor, Breast Cancer
Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy
To determine the Maximally Tolerable Dose (MTD) of KOS-1022 when administered weekly in combination with trastuzumab or in combination with trastuzumab and paclitaxel to patients with advanced solid tumor malignancies
- Trial name
- NCT00803556
- Testing
- Alvespimycin, Trastuzumab, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Bristol-Myers Squibb
Advanced Malignant Solid Neoplasm, Advanced Peritoneal Malignant Mesothelioma
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
This phase I/II trial studies the side effects and the best dose of methoxyamine when given together with cisplatin and pemetrexed disodium and to see how well it works in treating patients with solid tumors or mesothelioma that…
- Conditions
- Advanced Malignant Solid Neoplasm, Advanced Peritoneal Malignant Mesothelioma, Advanced Pleural Malignant Mesothelioma, Recurrent Peritoneal Malignant Mesothelioma
- Trial name
- NCT02535312
- Testing
- Cisplatin, Methoxyamine, Pemetrexed Disodium
- Where
- 14 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor
XTX301 in Patients With Advanced Solid Tumors
This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.
- Trial name
- NCT05684965
- Testing
- XTX301
- Where
- 12 sites in United States
- Volunteers
- 358 people
- Sponsor
- Xilio Development, Inc.
Solid Tumor
Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors
This is an open-label, Phase 1 dose-escalation study followed by a 2-arm expansion cohort of Oraxol administered in combination with pembrolizumab.
- Trial name
- NCT03588039
- Testing
- Oraxol, Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Athenex, Inc.
Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Arsenic Trioxide in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of arsenic trioxide in treating patients who have advanced…
- Trial name
- NCT00003630
- Testing
- arsenic trioxide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Ovarian Cancer
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have metastatic…
- Conditions
- Breast Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- BMS-247550 (NCT00005807)
- Testing
- BMS-247550
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Albert Einstein College of Medicine
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
This phase I trial studies the side effects and best dose of genetically modified T-cell therapy in treating patients with receptor tyrosine kinase-like orphan receptor 1 positive (ROR1+) chronic lymphocytic leukemia (CLL)…
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT02706392
- Testing
- Laboratory Biomarker Analysis, ROR1 CAR-specific Autologous T-Lymphocytes
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Fred Hutchinson Cancer Center
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas
This phase I trial studies the side effects and best dose of GSK525762C (molibresib besylate) and entinostat in treating patients with solid tumors or lymphomas that have spread to other parts of the body (advanced) or are not…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III T-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT03925428
- Testing
- Entinostat, Molibresib
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.